
Neurocrine Biosciences (NBIX) Stock Forecast & Price Target
Neurocrine Biosciences (NBIX) Analyst Ratings
Bulls say
Neurocrine Biosciences is well-positioned with a diverse portfolio of treatments in various stages of development, strong governance, and promising results from their phase II trial for a potential antidepressant. While there is potential for growth, challenges such as competition and regulation may affect the stock's performance. However, they are rated as a Buy and have a positive outlook with potential for higher growth if sales exceed expectations.
Bears say
Neurocrine Biosciences is a biopharmaceutical company that focuses on research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Despite a strong product portfolio and potential for future growth with upcoming pipeline catalysts, the company has faced recent challenges such as a recent stock pullback, competition in the market, and a potential slow uptake in initial market adoption. As a result, there are concerns about the sustainability and potential downside risks for the company's stock.
This aggregate rating is based on analysts' research of Neurocrine Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Neurocrine Biosciences (NBIX) Analyst Forecast & Price Prediction
Start investing in Neurocrine Biosciences (NBIX)
Order type
Buy in
Order amount
Est. shares
0 shares